Merkel Cell Carcinoma

2003 ◽  
Vol 127 (3) ◽  
pp. 367-369 ◽  
Author(s):  
Michael O. Idowu ◽  
Melissa Contos ◽  
Satinder Gill ◽  
Celeste Powers
Keyword(s):  
Gastrointestinal Bleeding ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Upper Gastrointestinal Bleeding ◽  
Neuroendocrine Differentiation ◽  
Neck Region ◽  
The Elderly ◽  
Merkel Cell ◽  
First Case ◽  
Upper Gastrointestinal

Abstract Merkel cell carcinoma (MCC) is an uncommon, highly aggressive cutaneous neoplasm of neuroendocrine differentiation with a poor prognosis. MCC most often presents as a painless, firm, raised lesion in sun-exposed sites of the head and neck region of the elderly. We report a case of a metastatic MCC to the stomach presenting as upper gastrointestinal bleeding. To our knowledge, this is the second reported case of MCC presenting as upper gastrointestinal bleeding and the first case confirmed by the newer immunohistochemical techniques. The literature is reviewed.

Merkel Cell Carcinoma: A Rare Cause of Upper Gastrointestinal Bleeding

2016 ◽  
Vol 111 ◽  
pp. S1088-S1089
Author(s):  
Alexander Kim ◽  
Jessica McKee ◽  
Joshua M. Shellenberger ◽  
Dana Stewart
Keyword(s):  
Gastrointestinal Bleeding ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Upper Gastrointestinal Bleeding ◽  
Merkel Cell ◽  
Upper Gastrointestinal

scholarly journals Role of Sentinel Lymph Node Biopsy in the Management of Merkel Cell Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Eric P. Arruda ◽  
Kevin M. Higgins
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neck Region ◽  
Lymph Node Biopsy ◽  
Merkel Cell ◽  
Treatment Protocols ◽  
Node Biopsy

Merkel cell carcinoma (MCC) is a rare and typically aggressive form of skin cancer. It most commonly affects the elderly and has a predilection for the sun-exposed skin of the head and neck region. Other etiological factors include immune suppression, organ transplantation, and polyoma virus infection. MCC has a propensity to spread to regional lymphatics with a high locoregional recurrence rate. Since its discovery in 1972, treatment paradigms have shifted, with no consensus on optimal management strategies. Currently, standard of care includes surgical intervention to the primary and locoregional site with adjuvant radiotherapy for high-risk disease. In this paper, we discuss the history, pathology, and epidemiology of this rare disease with a focus on the evidentiary basis of treatment protocols. The use of sentinel lymph node biopsy as a management option will be the focus of this paper.

A rare case of Merkel cell carcinoma presenting with an upper gastrointestinal bleed: a case report

2021 ◽  
pp. 1
Author(s):  
Georgina Simpson ◽  
Kalliopi Alexandropoulou ◽  
Panagiotis Koliou ◽  
Izhar Bagwan ◽  
Christopher Alexakis
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Rare Case ◽  
Merkel Cell ◽  
Gastrointestinal Bleed ◽  
Upper Gastrointestinal Bleed ◽  
Upper Gastrointestinal

Merkel Cell Carcinoma of the Eyelid: A Case Report

2000 ◽  
Vol 10 (2) ◽  
pp. 173-176 ◽  
Author(s):  
L. Collaço ◽  
J.P. Silva ◽  
M. Gonçalves ◽  
P. Abrantes
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Tumour ◽  
The Elderly ◽  
Primary Site ◽  
Wide Resection ◽  
Merkel Cell ◽  
Unique Case ◽  
Upper Eyelid

A 22-year-old woman who presented with a tumour of the upper eyelid with clinical, histological, immunohistochemical and ultrastructural features of a Merkel cell carcinoma is reported. This is a unique case of Merkel cell carcinoma in such a young patient. This neuroendocrine tumour is typically found in the elderly. It can grow rapidly, has the potential for local recurrence and early metastatic spread. The authors recommend wide resection of the primary site, which proved effective in this case.

scholarly journals Upper Gastrointestinal Bleeding Due to Metastatic Gastric and Duodenal Squamous-Cell Carcinoma from the Hypopharynx

Endoscopy ◽  
1996 ◽  
Vol 28 (02) ◽  
pp. 262-262
Author(s):  
C. S. Wu ◽  
C. M. Chen ◽  
S. Y. Tung ◽  
K. Y. Chang ◽  
T. C. Chen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Gastrointestinal Bleeding ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Upper Gastrointestinal Bleeding ◽  
Upper Gastrointestinal

Is CTLA4 targeting the Achilles’ heel of Merkel cell carcinoma?

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21567-e21567
Author(s):  
Richard Cheng Han Wu ◽  
Kari Lynn Kendra ◽  
Dukagjin Blakaj ◽  
Hiral A. Shah ◽  
Joanne M. Jeter ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Stage Iv ◽  
Lymph Node Involvement ◽  
Primary Objective ◽  
Merkel Cell ◽  
Number Of Patients

e21567 Background: Merkel Cell Carcinoma (MCC) is a cutaneous malignancy with neuroendocrine differentiation, linked to infection with polyomavirus (MCPyV) in 80% of cases. PD1 inhibitors have recently been approved for this indication with ORR, 33-56%; CR, 11-24%; PFS, about 17 months; OS, about 12 months. Nivolumab was tested in the neoadjuvant setting with similar responses with pathological CR, 47%. Methods: Adjuvant pilot study (NCT03798639) with two immunotherapy regimens administered for one year to patients with completely resected MCC at high risk of recurrence (primary lesion of 2 cm or greater, positive or close margins ( < 2 cm), perineural or lymphovascular invasion, mitotic index ≥ 20 mitotic figures per mm2, lymph node involvement (stage pIIIA or pIIIB) with or without extracapsular extension, or completely resected stage IV disease). Arm 1, nivolumab 480 mg q 4 wks and radiation therapy (RT) 50-60 Gy in 25-30 fractions, per standard of care. Arm 2, nivolumab 240 mg q 2 wks and ipilimumab 1 mg/kg q 6 wks. Primary objective was feasibility and completion of treatment in this population. Safety profile (CTCAE v5.0) and recurrence-free survival (RFS) after 18 months were secondary endpoints. Patients were randomly allocated 1:1. Results: Ten patients were screened from January 2019 until April 2020, when COVID put the study on hold and the sponsor discontinued the free drug supply. Seven were enrolled. Four were allocated to Arm 1 and three to Arm 2. Patient characteristics in Table. All patients have completed treatment and are in follow-up. Arm 1: all four patients completed radiation therapy and immunotherapy with no dose modifications or delays. Arm 2: one patient had nivolumab delayed 2 weeks for cellulitis, and another missed the last four last doses of nivolumab for cholecystitis and pancreatitis requiring surgery, unrelated to the immunotherapy. Adverse events (AE) were as expected. Arm1 caused more grade 2 and 3 AEs then Arm2 (no grade 3). One patient each discontinued treatment, in Arm 1 for progression and Arm 2 for immunotoxicity (temporal arteritis grade 2). One recurrence was observed in Arm 1 and none in Arm 2. Conclusions: The number of patients expected to recur at 1 year is 20%. Our observed data is insufficient to establish efficacy. However with no patient recurring in the ipilimumab arm after 18 months of follow-up and lower observed side effects, we would favor this regimen for the next trial. Clinical trial information: NCT03798639. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document